Skip Navigation LinksHome > January 2012 - Volume 20 - Issue 1 > Update on Preventing Pneumococcal Disease in Adults
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e3182452f39
NFID Clinical Updates

Update on Preventing Pneumococcal Disease in Adults

File, Thomas M. Jr MD, MSc*†; Hogue, Michael D. PharmD; Nichol, Kristin L. MD, MPH, MBA§∥; Schaffner, William MD



In the article by File et al, appearing in Infectious Diseases in Clinical Practice, Vol. 20, No. 1, pp. 3–9, entitled “Update on Preventing Pneumococcal Disease in Adults”, the following commercial support information was inadvertently omitted from the submission: “This activity is supported by an unrestricted educational grant from Merck & Co., Inc.”

Infectious Diseases in Clinical Practice. 21(1):74, January 2013.

Collapse Box


Abstract: Invasive pneumococcal disease (IPD) is responsible for substantial clinical and economic burden in adults. Despite the safety and effectiveness of pneumococcal vaccines in protecting against these serious infections, immunization of eligible adults remains largely underused. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has recently expanded the use of the pneumococcal vaccine to include adults with asthma and all cigarette smokers, in addition to persons previously designated as at-risk. Improving adult pneumococcal immunization rates will require efforts from a broad range of healthcare providers. Clinicians should take a proactive approach in recommending the vaccine to eligible adults and should implement strategies that remove barriers to immunization efforts.

© 2012 Lippincott Williams & Wilkins, Inc.

Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.